The running news file.

GH Research and Beckley Psytech are both building clinical programs around the 5-MeO-DMT / mebufotenin layer. The useful map keeps the assets separate: GH001 is an inhaled mebufotenin program; BPL-003 is an intranasal 5-MeO-DMT benzoate program.

Texas has authorized and announced a $50 million ibogaine research push led by UTHealth Houston, with UTMB Health and a statewide IMPACT consortium named. The careful read: selected and announced, but not yet safely described as contracted, enrolling, or running.

GH001 is the clinical-program name. Mebufotenin and 5-MeO-DMT are the compound-name layer around it. Keeping those labels separate makes the phase 2b signal easier to read: promising, source-backed, and still not the same as pivotal proof.

The Justice Department says FDA-approved marijuana products and qualifying state-licensed medical marijuana products are moving into Schedule III immediately, but broader marijuana rescheduling, and much of the tax relief investors are betting on, still depends on a separate June hearing and who actually qualifies.

A compact, source-by-source view of what different outlets say the Trump White House order changes, what they emphasize, and where the coverage diverges.

Helus says Michael Cola stepped down at the board's request and Eric So is back as interim CEO. The sharper fact is timing: the company hired Cola on Feb. 10 and removed him 69 days later without a public explanation.

The White House order is broader than ibogaine alone, but the first wave of coverage is right to center ibogaine, veterans, faster FDA review, and a new federal funding push.

After the FDA rejected Lykos' MDMA therapy application, MAPS shifted toward policy, education, and the long game.

The best-supported answer still begins at 5-HT2A, but the downstream story on plasticity and biomarkers is much less settled.

First full week roundup.

Cybin's CYB003 program is recruiting in phase 3, Mount Sinai is running an MDMA therapist-training study, Brigham has a severe alcohol use disorder protocol queued up, and smaller psilocybin studies in OCD and antidepressant interaction remain active.

Indiana University has posted a not-yet-recruiting psilocybin protocol for veterans and first responders with treatment-resistant depression and co-occurring substance use disorder. Johns Hopkins' OCD study is active but no longer recruiting. UC Irvine is recruiting an ibogaine neuroimaging study in opioid use disorder.

Oregon's regulated psilocybin program is real and growing, while Washington's SB 5921 remains stuck in committee.

How Richard Alpert became Ram Dass, why Be Here Now mattered, and how his path diverged from Timothy Leary's while still sharing psychedelic roots.

The journal said authors withheld protocol violations at the MP4 study site and failed to fully declare competing interests.

Otsuka is buying Transcend for up to $1.225 billion around a methylone PTSD program that has already reached Phase 3.

A Senate bill would establish a VA office for novel therapeutics. A large microdosing diary study found stronger same-day effects than durable carryover. GH001's FDA hold is over, and ibogaine's mechanism looks even stranger up close.

UNM's new Phase 1 PTSD study asks whether psilocybin-assisted therapy can be delivered safely in a peer-supported group format.

How a Mazatec healer in Huautla de Jiménez and a New York banker became central, unequal figures in the story of how psilocybin entered Western public awareness.

How Albert Hofmann's Sandoz compound moved from laboratory chemistry into psychiatry, Cold War intelligence programs, and the American counterculture.

GH001's FDA clinical hold is over, and the program now has a peer-reviewed phase 2b paper in JAMA Psychiatry. That is real progress, but it is not the same thing as pivotal proof or an FDA endorsement of efficacy.

Someone asked. So here we are.

The paper behind the headline did find DMT and harmine in a 1,000-year-old ritual bundle from southwestern Bolivia. It did not prove a prepared ayahuasca brew. What it does show is broader and more defensible: multiple psychoactive plants, long-distance movement, and sophisticated botanical knowledge in the pre-Columbian Andes.

Compass says FDA accepted its PTSD IND, while RAND finds 23% of Americans support legal psilocybin mushrooms.